NFKB1 and colitis: In chemically induced colitis, EPO treatment was suggested to inhibit induction of activated macrophages and expression of proinflammatory genes such as inducible NO synthase (iNOS/NOS2), TNF-α, interleukin 6, and blocks NF-κB activation to limit tissue damage in the gut [183].